Paper Details

  1. Home
  2. Paper Details

Optimal treatment of early-stage ovarian cancer.

Author: , CollinsonF, ColomboN, FossatiR, LedermannJ, LissoniA, ParmarM, QianW, SwartA, WilliamsC

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This report provides 10-year follow-up data on the ICON1 trial, which evaluated the benefits of adjuvant chemotherapy for early-stage ovarian cancer. Results demonstrate long-term benefits in overall survival and recurrence-free survival, supporting the use of adjuvant chemotherapy in this setting.
Paper Details　
Original Abstract of the Article :
There is no clear consensus regarding systemic treatment of early-stage ovarian cancer (OC). Clinical trials are challenging because of the relatively low incidence and good prognosis. Initial results of the International Collaborative Ovarian Neoplasm (ICON)1 trial demonstrated benefit in both over...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4037858/

データ提供：米国国立医学図書館（NLM）

Navigating the Labyrinth of Early-Stage Ovarian Cancer Treatment

In the vast desert of cancer research, ovarian cancer presents a unique challenge. Early-stage ovarian cancer, while often treatable, requires careful navigation. The researchers in this study are like intrepid explorers, seeking the best path through this challenging terrain. They are looking for the optimal treatment for early-stage ovarian cancer, which is a type of cancer that can be tricky to treat, like a mirage that sometimes disappears. Their research explores the benefits of adjuvant chemotherapy after surgery, which is like equipping the explorers with powerful tools to fight the cancer.

Adjuvant Chemotherapy: A Weapon Against Ovarian Cancer Recurrence

Their findings suggest that adjuvant chemotherapy can be a powerful weapon against ovarian cancer recurrence. This treatment helps to prevent the cancer from returning, like a protective barrier against the harsh desert winds. The study also underscores the importance of long-term follow-up to ensure the benefits of treatment persist. It's like a desert oasis that keeps the explorers nourished and strong.

Hope for Patients and a Call for Further Research

This research offers hope for patients with early-stage ovarian cancer, as it highlights the potential of adjuvant chemotherapy. It also emphasizes the need for more clinical trials to further refine treatment strategies. We need more research to find the optimal treatment for this challenging disease, like finding a new path through the shifting sands.

Dr.Camel's Conclusion

This study, like a compass in the desert, guides us toward a better understanding of early-stage ovarian cancer treatment. The researchers' efforts provide valuable insights for clinicians and patients, paving the way for improved outcomes.

Date :
  1. Date Completed 2015-01-21
  2. Date Revised 2022-04-10
Further Info :

Pubmed ID

24631948

DOI: Digital Object Identifier

PMC4037858

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.